ライフサイエンスコーパス: DR

1 DR cell population was greatly expanded in the Tr(-/-)Md

2 DR cells appear to play a key role in recruiting immune

3 DR lesion parameters that conferred a statistically sign

4 DR was calculated as the proportion of PSMA PET-positive

5 DR was graded by standard methods as either low risk (no

6 DR-18 also enhanced the activity and maturation of natur

7 DR-A is well-suited for unsupervised learning tasks for

8 DR-A leverages a novel adversarial variational autoencod

9 DR/DQ-SE also interacted with neighboring CTCF binding s

10 Repeated OCTA scans of 15 normal eyes and 12 DR eyes were obtained.

11 on, we engineered a 'decoy-resistant' IL-18 (DR-18) that maintains signalling potential but is imperv

12 Unlike wild-type IL-18, DR-18 exerted potent anti-tumour effects in mouse tumour

13 ely 30% of ranibizumab-treated eyes achieved DR ultra-response at year 1 (43/148; 29.1%) and year 2 (

14 ts that received <=100 ml of contrast agent (DR n = 26: Deltacreatinine -0.03(-0.20,0.08)mg/dL vs. co

15 d in patients with <=2 risk factors for AKI (DR: n = 27; Deltacreatinine -0.01(-0.18,0.07)mg/dL vs. c

16 increasing population suffering from AMD and DR, there is an urgent need to develop new therapeutics

17 ocumented chart standard for stage of DR and DR-related complications.

18 g for stage of diabetic retinopathy (DR) and DR-related complications (including vitreous hemorrhage,

19 values were compared between the normal and DR eyes.

20 We find that undernutrition, obesity, and DR-NCDs are intrinsically linked through early-life nutr

21 ed risks of poor quality diets, obesity, and DR-NCDs, especially in countries undergoing a rapid nutr

22 he risk of both undernutrition, obesity, and DR-NCDs.

23 Predominantly peripheral lesions (PPL) and DR severity were graded from UWF color images.

24 Patients with T2D and DR had smaller PIPR and lower urinary aMT6s than other g

25 Here we use high-throughput and DR subdomain-targeted single-cell transcriptomics and in

26 cy, activated CD38+Human Leukocyte Antigen - DR isotype (HLA-DR)+ CD4 and CD8 T cells and negatively

27 nts stratified using human leukocyte antigen-DR expression on monocytes (mHLA-DR).

28 he indirect SBFI approach (0.79/0.99 for any DR and 1.0/1.0 for severe DR, 0.79/1.0 for diabetic macu

29 indications for RLT were preventable such as DR, DMO and RVO, indicating need to control systemic dis

30 ystems to perform DR screening and automated DR detection using image processing methods.

31 On average, DR extended lifespan and delayed decline in climbing abi

32 s are significantly associated with baseline DR severity, disease progression, and treatment requirem

33 ting a positive severity correlation between DR and DPN.

34 The correlation between DR and patient characteristics was evaluated.

35 Boulware DR, Pullen MF, Bangdiwala AS, et al.

36 CD11bCD33CD14CD15HLA-DR (monocytic MDSC [M-MDSC]) and CD11bCD33CD14CD15HLA-DR

37 ytic MDSC [M-MDSC]) and CD11bCD33CD14CD15HLA-DR (monocytes), were defined by flow cytometry.

38 tivated CD8 (CD8+CD38+DR+) and CD4 (CD4+CD38+DR+) T cells in 586 women who were naive to highly activ

39 s and percentages of activated CD8 (CD8+CD38+DR+) and CD4 (CD4+CD38+DR+) T cells in 586 women who wer

40 or Alzheimer's Disease Delayed Recall (CERAD-DR) and Word Learning tests, and the Animal Fluency test

41 rum total folate was protective on the CERAD-DR.

42 g clinically relevant data to manage complex DR-TB cases.

43 ly of the microvascular alterations defining DR.

44 0.868) and sensitivity/specificity to detect DR were highest for the indirect SBFI approach (0.79/0.9

45 te insurance but were less likely to develop DR (OR, 0.71; P < 0.01).

46 4; P < 0.01) and were more likely to develop DR at 5 years (OR, 1.17; P < 0.01) than women.

47 n eye examination and less likely to develop DR.

48 e control group did not show any difference (DR: 0.03(-0.15,0.14)mg/dL vs. control: 0.09(-0.03,0.22)m

49 Compared with the stage of DR, DR-related diagnoses were overall less accurately coded

50 a causative role in visual defects in early DR.

51 2016-February 2018, 32 of 198 (16%) enrolled DR-TB HIV patients were identified as dual adherence-cha

52 ic day 7.5 (T-E7.5), in the adult the entire DR and part of the median raphe (MnR) have Fgf8 lineage.

53 The expanded DR cell population in Tr(-/-)Mdr2(-/-) mice was due to d

54 Finally, DR cells were noted to be primed for apoptosis with Bcl-

55 ntaenoic acid (EPA), are increased following DR and these PUFAs are able to activate the CyTP genes.

56 xamination time, and diagnostic accuracy for DR screening were analyzed against conventional fundus p

57 of image quality and diagnostic accuracy for DR screening.

58 oved performance than multiple baselines for DR analysis.

59 the RSClin risk estimate was prognostic for DR risk in the Clalit registry (P < .001) and the estima

60 election of SBFI devices in field trials for DR screening.

61 s, it would be reasonable to perform further DR-related OCTA studies in this population and expect ge

62 Brief Negotiated Interview for Oral Health (DR-BNI)-in reducing the recurrence of dental caries in c

63 autoantibodies, irrespective of class II HLA DR-DQ genotype.

64 f FPIR with genetic variants outside the HLA DR-DQ region in the Finnish Type 1 Diabetes Prediction a

65 ptor 5 (CCR5), human leukocyte antigen (HLA) DR isotope, and cluster of differentiation 38 (CD38) exp

66 HLA-DR, CD3, CD28, CD40 and CD 138 significantly increased w

67 d displayed higher levels of activation (HLA-DR(+)) and exhaustion (PD1(+)) markers.

68 and levels of T-cell immune activation (HLA-DR+CD38+).

69 with inducible costimulator molecule and HLA-DR defining midterm and long-term T-cell activation, res

70 turation, illustrated by CD86, CD83, and HLA-DR upregulation and their migration out of the epidermis

71 ls and CTLs, and between tumor cells and HLA-DR(+) macrophages, but not HLA-DR(-) macrophages.

72 lls, implying that CLEC16A controls both HLA-DR/CD74 and BCR/Ag processing in MIICs.

73 Accumulation of CD14(+)HLA-DR(low) monocytic MDSCs has been described in newly diag

74 primary outcome measured change in %CD38+HLA-DR+ CD8+ T cells.

75 cant declines were observed in the %CD38+HLA-DR+CD8+ T cells at 24-48 (-4.0%, P = .001) and 72-96 (-7

76 (+)CSF1R(+) at higher levels than CD68(+)HLA-DR(+) macrophages, consistent with an M2 phenotype.

77 higher expression levels of CD83, CD86, HLA-DR and CD54, increased secretion of IL12 and IL10 and hi

78 ion of HLA-DR in tumor epithelial cells; HLA-DR expression was also significantly higher in the tumor

79 ssociated with the abundance of effector HLA-DR(+)CD8(+) T cells.

80 for DSA at 1 year was 0.84 and 0.82 for HLA-DR and HLA-DQ eplet mismatches, respectively.

81 Self-peptides from HLA-DR molecules, particularly from DR2a and DR2b themselves

82 ells were activated, reflected as higher HLA-DR and CD38 expression.

83 , and B (P < 0.0001) lymphopenia, higher HLA-DR expression on monocytes (P < 0.001) and higher serum

84 el endogenously expressing MHC class II (HLA-DR), this study shows that HCMV decreases the expression

85 The decrease in HLA-DR expression was independent of the expression of previ

86 ation but was a result of a reduction in HLA-DR transcripts due to a decrease in the expression of th

87 tion. Using a vaccine-challenge model in HLA-DR transgenic mice, we demonstrated significant alterati

88 IFN-alpha increased HLA-DR, CD80, CD86, and PD-L1 expression on healthy donor mo

89 ene signature in monocytes and increased HLA-DR, CD80, CD86, and PD-L1 expression.

90 38+Human Leukocyte Antigen - DR isotype (HLA-DR)+ CD4 and CD8 T cells and negatively with Dectin-1 an

91 Finally, CLIP-loaded HLA-DR molecules were abnormally enriched, and coregulation

92 Antigen-presenting cells had low HLA-DR and CD86 expression, potentially indicative of impair

93 T helper 2 signature; recruitment of low HLA-DR expressing monocytes and regulatory T-cells; and tran

94 two subsets of interstitial macrophages (HLA-DR(+)CD206(-)): a transitional CD11c(+)CD16(+) cell popu

95 ly-stage MDSCs and >40% monocytic MDSCs (HLA-DR(-)CD14(+)MDSCs).

96 ing MDSCs were mainly early-stage MDSCs (HLA-DR(-)CD33(+)CD14(-)CD15(-)MDSCs).

97 ted of >35% ARG1-expressing naive MDSCs (HLA-DR(-)CD33(-)CD11b(-)CD14(-)CD15(-)MDSCs), >15% early-sta

98 cells and HLA-DR(+) macrophages, but not HLA-DR(-) macrophages.

99 ch includes an upregulated expression of HLA-DR and CD86 molecules and increased production of TNF-al

100 rojections and had reduced expression of HLA-DR and CD86, suggesting that Ag processing and T cell ac

101 ws that HCMV decreases the expression of HLA-DR in infected cells by reducing the transcription of HL

102 set of TNBCs have elevated expression of HLA-DR in tumor epithelial cells; HLA-DR expression was also

103 d cells by reducing the transcription of HLA-DR transcripts early during infection independently of t

104 Furthermore, immunization of HLA-DR transgenic mice with a mixture of the two immunodomin

105 Immunization of HLA-DR transgenic mice with a mixture of these two immunodom

106 The altered surface level of HLA-DR was not a result of increased endocytosis and degrada

107 nts with IBD had increased abundances of HLA-DR+CD38+ T cells, including T-regulatory cells that prod

108 manner via single-cell RNA sequencing on HLA-DR(+) cells sorted from human lungs.

109 react with HLA-DR-derived self-peptides (HLA-DR-SPs), peptides from MS-associated foreign agents (Eps

110 therapeutic concentrations with several HLA-DR molecules.

111 s resulted in an upregulation of surface HLA-DR and CD74 (invariant chain), whereas CLIP was slightly

112 the peptide-binding pocket 7 (P7) of the HLA-DR heterodimer, suggesting that these alterations might

113 The HLA-DR(-) subset coexpressed CD163(+)CSF1R(+) at higher leve

114 T cell clones that can cross-react with HLA-DR-derived self-peptides (HLA-DR-SPs), peptides from MS-

115 ur findings reveal that the activity of 5-HT(DR->VTA) neurons may be an essential factor in determini

116 ion in the DR that projects to the VTA (5-HT(DR->VTA) neurons).

117 stress decreased the firing activity of 5-HT(DR->VTA) neurons.

118 ion-relaxation correlation spectrum imaging (DR-CSI) in the characterization of microstructural tissu

119 s may improve progression risk assessment in DR when compared to established risk factors alone.

120 Reduced ipRGC function in DR is associated with circadian dysregulation and sleep

121 We explored whether ipRGC function in DR is associated with circadian outputs and sleep/wake b

122 GPD percentages were significantly higher in DR eyes than in normal eyes; vessel density percentages

123 ion groups showed significant improvement in DR severity at month 12 compared with baseline.

124 ession was defined as a >=2-step increase in DR severity scale score or development of diabetic macul

125 r structures, the vascular/neural network in DR and the retinal pigment epithelium (RPE) in AMD.

126 esent study, we examined the role of PKM2 in DR in a mouse model that has both phenotypes of obesity

127 of the pathogenic changes that take place in DR.

128 rtphone camera demonstrates its potential in DR screening.

129 enation and morphology have been reported in DR, there is limited knowledge about these vascular chan

130 Our studies suggest that PKM2 has a role in DR.

131 hree pairwise comparisons of the severity in DR (NoDR vs NPDR, controls vs NPDR, and controls vs NoDR

132 All individual DR lesions (hemorrhage [H], microaneurysm [ma], cotton w

133 Patients who initiated DR-TB treatment including BDQ and DLM (concomitantly for

134 istocompatibility complex, class II, isotype DR beta I; major histocompatibility complex, class I, C;

135 d 16 after 2008) in Cameroon, Cote d'Ivoire, DR Congo, Ethiopia, Guinea, Kenya, Lesotho, Liberia, Mal

136 l subpopulation (dorsal region of the medial DR) had increased.

137 Smartphone-based fundus imaging can meet DR screening requirements in an outreach setting; howeve

138 files: healthy volunteers, intermediate mHLA-DR septic shock patients, and low mHLA-DR septic shock p

139 mHLA-DR septic shock patients, and low mHLA-DR septic shock patients.

140 yte antigen-DR expression on monocytes (mHLA-DR).

141 ndard methods as either low risk (no or mild DR) or high risk (moderate or severe DR).

142 median MELD at LT was 20, 21, and 24 for ML-DR, ML-SR, and SL groups, respectively (P = 0.001).

143 lowest quartiles [Q2-4 vs. Q1]) and moderate DR (stage 3 or more) were analyzed using multivariate ge

144 up, 15% of adolescents demonstrated moderate DR.

145 ) before surgery, eyes with mild or moderate DR gained 10.0 letters (IQR, 5.0-22.0) from 65.0 (IQR, 5

146 one retinal vessel caliber predicts moderate DR in adolescents with type 1 diabetes.

147 E and CRVE were not associated with moderate DR.

148 seful biomarker for detecting and monitoring DR.

149 Subjects were subdivided into no DR, mild nonproliferative DR (NPDR), moderate NPDR, prol

150 sis, non-negative matrix factorization or no DR.

151 fidence interval [CI], 92-100 mum) versus no DR (103 mum; 95% CI, 100-106 mum) eyes and only after ex

152 Exclusion criteria were non-DR retinal disease and inability to image the macula.

153 Of these, 3 eyes had mild nonproliferative DR (NPDR), 6 eyes had moderate NPDR, 4 eyes had severe N

154 subdivided into no DR, mild nonproliferative DR (NPDR), moderate NPDR, proliferative DR, and prolifer

155 of 193 patients (24.9% mild nonproliferative DR [NPDR], 22.8% moderate NPDR, 37.5% severe NPDR and 14

156 ients with mild to moderate nonproliferative DR (NPDR), and 12 diabetic patients with severe NPDR to

157 and eyes with mild/moderate nonproliferative DR (NPDR; n = 125), severe NPDR (n = 20), and proliferat

158 inopathy (DR) (n = 68); the nonproliferative DR (NPDR) group (n = 48); and the proliferative DR (PDR)

159 stem raphe nuclei, the dorsal raphe nucleus (DR) contains the greatest number of Pet1-lineage neurons

160 aging might aid in alleviating the burden of DR screening in low- and middle-income countries, and th

161 until March 2017, all household contacts of DR-TB patients enrolled at the Indus Hospital were scree

162 Importantly, deletion of DR/DQ-SE reduced the local chromatin interactions, imply

163 Deletion of DR/DQ-SE resulted in reduced expression of HLA-DRB1 and

164 e importance of ZFPM1 for the development of DR serotonergic neuron subtypes involved in mood regulat

165 to map molecular and anatomical diversity of DR-Pet1 neurons.

166 and p38-MAPK pathway function downstream of DR to help communicate the metabolic state of an organis

167 RSClin estimates of DR used a baseline risk with TAILORx event rates to refl

168 of this trial suggest a beneficial impact of DR in low-to-moderate risk patients.

169 revealed a significant beneficial impact of DR in patients that received <=100 ml of contrast agent

170 y evaluations conducted at the initiation of DR-TB treatment.

171 Here, using a genetic model of DR, we show that the levels of polyunsaturated fatty aci

172 points were any progression of DR, onset of DR, and progression from mild to severe DR tracked from

173 thway are required for multiple paradigms of DR-mediated longevity, suggesting conservation of mechan

174 temporal peripapillary VD are predictors of DR progression.

175 ,4-DHBA was a risk marker for progression of DR (n = 133) after adjustment (P = 0.033).

176 End points were any progression of DR, onset of DR, and progression from mild to severe DR

177 Hispanic patients had higher rates of DR (OR, 1.60; P < 0.01) and received fewer eye examinati

178 ng/ml versus >8 ng/ml had increased risk of DR/DQ DSA at 1 year (HR 2.34, 95% CI 1.05-5.22, p = .04)

179 ents, there was a graded increase in risk of DR/DQ DSA in intermediate (HR 15.39, 95% CI 2.01-118.09,

180 Severity of DR at baseline, month 6, and month 12 was evaluated usin

181 A masked grader determined the severity of DR from the color photographs using the Early Treatment

182 l layer structuring based on the severity of DR.

183 d deletion or acute optogenetic silencing of DR(Sert) neurons dramatically increased the latency of m

184 d the documented chart standard for stage of DR and DR-related complications.

185 Stage of DR was measured every 6 months from standard fundus phot

186 Compared with the stage of DR, DR-related diagnoses were overall less accurately co

187 oss is more pronounced in advanced stages of DR, indicating a positive severity correlation between D

188 A prospective study of DR-TB HIV patients on antiretroviral therapy (ART) initi

189 le Zfpm1 mutants, a lateral subpopulation of DR neurons (ventrolateral part of the DR) was lost, wher

190 entiation of serotonergic neuron subtypes of DR.

191 s between PCa and benign tissues in terms of DR-CSI signal components and microscopic tissue compartm

192 ffordable retinal imaging systems to perform DR screening and automated DR detection using image proc

193 PET DR among all patients was 80%.

194 We further show that P2ry1-Pet1 DR neurons - the most molecularly distinct subtype - pos

195 When applied to this preliminary DR data set, our density-based method demonstrated bette

196 e-based treatment for contacts with presumed DR-TB infection is feasible and well tolerated in a high

197 yet lack of resources has largely prevented DR screening implementation in these world regions.

198 These data complement and extend previous DR characterizations, combining intersectional genetics

199 iological functions of these ancient primary DR sequences remain largely unknown.

200 R, 37.5% severe NPDR and 14.7% proliferative DR [PDR]) were reviewed.

201 25), severe NPDR (n = 20), and proliferative DR (PDR; n = 72) were included.

202 te NPDR, proliferative DR, and proliferative DR with fibrosis.

203 es had severe NPDR, 9 eyes had proliferative DR, and 4 eyes were normal controls.

204 which are comprised of 38 non-proliferative DR (NPDR), 28 without DR (NoDR), and 41 controls.

205 tive DR (NPDR), moderate NPDR, proliferative DR, and proliferative DR with fibrosis.

206 (NPDR) group (n = 48); and the proliferative DR (PDR) group (n = 41).

207 c patients with severe NPDR to proliferative DR.

208 To overcome these difficulties, we propose DR-A (Dimensionality Reduction with Adversarial variatio

209 he two systems, we showed that dorsal raphe (DR) 5HT neurons selectively targeted the PBel.

210 onal populations including the dorsal raphe (DR) nucleus.

211 a serotonergic input from the dorsal raphe (DR) to ventral tegmental area (VTA) influences vulnerabi

212 Main endpoints were the detection rate (DR) and false-negative rate (FNR) of TLNB and TAD after

213 tive study was to assess the detection rate (DR), positive predictive value (PPV), and correct detect

214 olestatic liver diseases, ductular reactive (DR) cells extend into the hepatic parenchyma and promote

215 ver injury, fibrosis, and ductular reactive (DR) cells.

216 Test intervention parents (n = 119) received DR-BNI led by trained dental nurses.

217 97 patients with diabetes who were receiving DR screening examinations, including 7-field fundus phot

218 s/m(2)) occur prior to clinically recognized DR.

219 A-type and delayed-rectifier (DR) potassium currents, two putative transcriptional tar

220 a mouse model of chronic cholestasis reduces DR-cell and B-cell populations and hepatic fibrosis.

221 Dimensionality reduction (DR) methods have been developed to mitigate these challe

222 e elements with auxin-induced up-regulation (DR and IR) or down-regulation (IR) was correlated with d

223 containing 60% of daily energy requirement (DR group) or ad-libitum food during the 4-day-interval b

224 Defect resolution (DR) and bone filling (BF) were used for radiographic ana

225 ce two new filters, the distance-restraints (DR) and the Symmetry-Imposed Packing (SIP) filters.

226 Dietary restriction (DR) is the most robust means to extend lifespan and dela

227 Short-term dietary restriction (DR) may prevent organ damage from ischemic or toxic insu

228 Dietary restriction (DR), which positively affects health and life span acros

229 ps: the groups without diabetic retinopathy (DR) (n = 68); the nonproliferative DR (NPDR) group (n =

230 dications for RLT were diabetic retinopathy (DR) and diabetic macular oedema (DMO) (542 cases, 66.0%)

231 of coding for stage of diabetic retinopathy (DR) and DR-related complications (including vitreous hem

232 Diabetic retinopathy (DR) is a common complication of diabetes and a leading c

233 Diabetic retinopathy (DR) is a severe retinal disorder that can lead to vision

234 Diabetic retinopathy (DR) is diagnosed clinically by directly viewing retinal

235 atures associated with diabetic retinopathy (DR) may improve assessment and treatment of disease prog

236 dG) as a biomarker for diabetic retinopathy (DR) screening.

237 Diabetic retinopathy (DR), the most common cause of vision loss, is caused by

238 markers associated to diabetic retinopathy (DR).

239 vein occlusion (RVO), diabetic retinopathy (DR; diabetic macular edema, DME), or noninfectious uveit

240 high-risk patients classified by DGM-CM6 (RI-DR) had significant differences in 10-year distant recur

241 seudocolor, and retromode deviated to right (DR) and left (DL).

242 obally should scale up access to life saving DR-TB regimens with new drugs.

243 (0.79/0.99 for any DR and 1.0/1.0 for severe DR, 0.79/1.0 for diabetic maculopathy).

244 or mild DR) or high risk (moderate or severe DR).

245 t of DR, and progression from mild to severe DR tracked from standard ambulatory care and investigate

246 arouse during hypercapnia, as did silencing DR(Sert) terminals in the PBel.

247 Since DR is a silent disease that may cause no symptoms or onl

248 In this study, we revealed that the specific DRs are involved in the production of specific sfRNAs in

249 ndependent risk factor for 2-step and 3-step DR progression and PDR.

250 all imaging modalities, retromode technology DR and DL may be a potential supplementary modality to d

251 Our results indicate that DR-A significantly enhances clustering performance over

252 rlying assumption in the aging field is that DR enhances both lifespan and physical activity through

253 the basis of these findings, we propose that DRs functions like a bracket holding the Xrn1-xrRNA comp

254 ng biased cell body distributions across the DR.

255 At baseline, the DR-BNI group's mean dmft was 6.8, and the control group'

256 ndicate that the serotonergic input from the DR to the PBel via 5HT(2a) receptors is critical for mod

257 Deltacreatinine post PCI in the DR group vs. the control group did not show any differen

258 ly defined serotonergic subpopulation in the DR that projects to the VTA (5-HT(DR->VTA) neurons).

259 elative risk of new caries experience in the DR-BNI group as compared with control.

260 tic deletion of TRAIL receptor increased the DR cell population, macrophage accumulation, and hepatic

261 In patients with PSA levels >= 1 ng/mL the DR and PPV were 90% and 91%, respectively, resulting in

262 In patients with PSA levels < 1 ng/mL, the DR and PPV were 69% and 85%, respectively, resulting in

263 -) mice resulted in further expansion of the DR cell population.

264 ion of DR neurons (ventrolateral part of the DR) was lost, whereas the number of serotonergic neurons

265 servation suggests that the magnitude of the DR-cell population may be regulated by apoptosis.

266 2(-/-) versus Mdr2(-/-) mice, suggesting the DR cell population promotes macrophage-associated hepati

267 tive nucleus that forms a major input to the DR.

268 onth 6, and month 12 was evaluated using the DR severity scale (DRSS).

269 ning of both WT and DKO ERCs confirmed their DR-cell phenotype.

270 that the base pairings in the stem of these DRs control sfRNA formation by maintaining the binding a

271 ly serotonergic group distributed throughout DR subdomains.

272 iabetes, imaging was classified according to DR severity by a telemedicine reading center.

273 eans of distinguishing patients according to DR severity.

274 essel density and FAZ-specific parameters to DR severity and BCVA.

275 s panel of metabolites and lipids related to DR in type 1 diabetes.

276 y 50% of strains showed positive response to DR for both lifespan and climbing ability, 14% showed a

277 r patients with drug-resistant tuberculosis (DR-TB) and limited therapeutic options, referred from ot

278 als treated for drug-resistant tuberculosis (DR-TB) with aminoglycosides (AGs) in resource-limited se

279 e infected with drug-resistant tuberculosis (DR-TB).

280 er, and instant coffee were determined using DR CALUX(R) bioassay, before and after intestinal metabo

281 We illustrate this by utilizing DR-A for clustering of scRNA-seq data.

282 ation that was equivalent to controls, vlPAG/DR threat responding was altered in adverse-experienced

283 results reveal long-lasting changes in vlPAG/DR threat responding resulting from early adolescent adv

284 elihood of visual impairment associated with DR is two-fold higher in the African-American (AA) compa

285 avascular zone size was not associated with DR severity when single OCTA images (P = 0.98) were cons

286 in the microvascular changes associated with DR.

287 sionally printed molds by using 3-T MRI with DR-CSI and were then sliced to create coregistered WMHP

288 At year 2, patients with DR ultra-response had gained more than 5 additional ETDR

289 surgery is beneficial in most patients with DR without severe concurrent macular pathologic features

290 This model may identify patients with DR-TB who are at highest risk of developing AG-induced o

291 retinal layers are affected in patients with DR.

292 f 38 non-proliferative DR (NPDR), 28 without DR (NoDR), and 41 controls.

293 re included in the study, 36 with DM without DR, 53 with mild NPDR, and 22 with moderate NPDR.

294 Diabetic eyes without DR (n = 138) and eyes with mild/moderate nonproliferativ

295 A year after surgery, eyes without DR gained a median of 11.0 Early Treatment Diabetic Reti

296 etic patients, 170 diabetic patients without DR, 57 diabetic patients with mild to moderate nonprolif

297 al ETDRS letters compared with those without DR ultra-response.

298 ved was similar for eyes with versus without DR ultra-response to ranibizumab (mean, 7.4 vs. 7.6 in y

299 ers were associated significantly with worse DR severity and BCVA.

300 ated with increasing nonperfusion, worsening DR severity and presence of PPL.

301 arteriolar diameter increased with worsening DR severity (mild NPDR: 10% vs PDR: 31%, P = 0.007).